147 related articles for article (PubMed ID: 35469834)
1. Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
Liu Q; Luo L; Gao X; Zhang D; Feng X; Yang P; Li H; Mao S
J Pharm Sci; 2023 Jan; 112(1):123-131. PubMed ID: 35469834
[TBL] [Abstract][Full Text] [Related]
2. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
4. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells.
Wang Y; Liu F; Wang Q; Xiang H; Jin H; Li H; Mao S
Int J Pharm; 2017 Aug; 529(1-2):531-542. PubMed ID: 28583331
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia.
Yan D; Wei H; Lai X; Ge Y; Xu S; Meng J; Wen T; Liu J; Zhang W; Wang J; Xu H
J Control Release; 2020 Nov; 327():766-778. PubMed ID: 32949646
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
8. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
[TBL] [Abstract][Full Text] [Related]
9. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS.
Xiong S; Yu B; Wu J; Li H; Lee RJ
Biomed Pharmacother; 2011 Feb; 65(1):2-8. PubMed ID: 21177069
[TBL] [Abstract][Full Text] [Related]
10. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
[TBL] [Abstract][Full Text] [Related]
13. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
14. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
[TBL] [Abstract][Full Text] [Related]
15. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
16. Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer.
Yang Y; Zhao Z; Xie C; Zhao Y
Chem Phys Lipids; 2020 May; 228():104882. PubMed ID: 32017901
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
18. Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo.
Liu B; Zhang J; Liu Z; Wang P; Zhang Y; He H; Yin T; Gou J; Tang X
Int J Pharm; 2023 Nov; 646():123500. PubMed ID: 37820944
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.
Liu FR; Jin H; Wang Y; Chen C; Li M; Mao SJ; Wang Q; Li H
Drug Deliv; 2017 Nov; 24(1):882-890. PubMed ID: 28574300
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]